Novo Nordisk

Rybelsus (oral semaglutide, diabetes label)

Novo publishes no cash price for Rybelsus, and the federal TrumpRx tablet is the Ozempic pill — a different strength on the same label.

All-in, per month

Price unverified

checked 2026-09-07 — the seller publishes no all-in priceVisit Rybelsus (oral semaglutide, diabetes label) ↗

List price: $1,028
Medication: brand
Form: pill
Price checked: 2026-09-07

RxNorm 2200645 for the product, 1991302 for the ingredient. The codes the US National Library of Medicine assigns, so this page names one specific thing rather than a brand that could mean several.

It carries a boxed warning — the strongest the FDA issues

In rodents this molecule caused thyroid C-cell tumors. Whether it does so in people is unknown, and the label carries that as a boxed warning. It is contraindicated outright with a personal or family history of medullary thyroid carcinoma or MEN 2.

From FDA prescribing information for RYBELSUS and OZEMPIC tablets. Everything the label lists, including who cannot take it →

Novo publishes no self-pay price for Rybelsus. TrumpRx, the federal direct-purchase site, lists oral semaglutide at $149 a month under the name Ozempic Pill, in 1.5 mg, 4 mg and 9 mg tablets — read 11 September 2026 — and the label the two share says those are not substitutable for the 3 mg, 7 mg and 14 mg Rybelsus tablets mg for mg. So no price is shown for Rybelsus.

What this page used to say

2026-09-11 — Rybelsus showed another tablet's price. Was: $149 a month, verified 2026-09-07. Now: No price: Novo publishes none for Rybelsus.
2026-09-11 — The date the label was published. Was: label published 2026-08-18. Now: label published 2026-08-19.
2026-09-11 — The catch printed under a savings program. Was: — a third of what Lilly allows on its cards for the same $25 headline. Now: — two-thirds of the $150 Lilly allows on its Mounjaro and Trulicity cards, and the same as its Zepbound card, for the same $25 headline.
2026-09-08 — The date the label was published. Was: label published 2026-01-30. Now: label published 2026-08-18.
2026-09-07 — A published cash price, where this page said none existed. Was: no verified cash price is published. Now: $149 a month.
2026-09-05 — Rebuilt the serious reactions as the label's section 5, in the label's order. Was: Six items: acute pancreatitis, diabetic retinopathy complications, acute kidney injury, gallbladder disease, hypoglycemia, pulmonary aspiration. Now: Eight, in label order: acute pancreatitis (5.2), diabetic retinopathy complications (5.3), hypoglycemia (5.4), acute kidney injury (5.5), severe gastrointestinal reactions (5.6), hypersensitivity reactions (5.7), acute gallbladder disease (5.8), pulmonary aspiration under anesthesia (5.9).

Every correction on this site, dated →

How much does Rybelsus (oral semaglutide, diabetes label) cost a month?

halfrx records no verified price for Rybelsus (oral semaglutide, diabetes label): nothing it publishes states an all-in monthly figure, so this medication carries no price here rather than a guess. What it costs once titrated is not published, which is a fact about the seller rather than a gap in the data. It carries one flag on this site: boxed warning. It scores 3.0 out of 10 on a published formula that is arithmetic over the facts on this page, not an editor's opinion. The medication is the branded, FDA-approved product rather than a compounded copy. The page rests on 3 cited sources, at least one of them a manufacturer, regulator or journal. Anything past 45 days without a re-check is marked stale here rather than quietly aging. Molecule: semaglutide.

Tracked since 2026-09-07. The $149 recorded then was withdrawn on 2026-09-11, because nothing the seller publishes supports it. Last corrected on 2026-09-11 — see what this page used to say, above.

No clinician has reviewed this page. Label and trial statements are quoted from the FDA label or the trial cited beside them. General guidance is marked as such, and every price carries the date it was verified. That is sourcing, not medical review. What we do and do not check · Who checked the price

Off-label for weightStrict dosing rulesNo published priceBoxed warning

What is good about Rybelsus?

+A tablet rather than an injection, and the only oral semaglutide with a diabetes indication.[1]
+Same molecule as Ozempic and Wegovy, so the mechanism is the one with the deepest evidence base.[1]

What are the downsides of Rybelsus?

−Novo publishes no cash price, so the figure anyone without insurance actually pays is not discoverable in advance.[1]
−The card caps Novo's contribution at $100 a month: with no coverage it does close to nothing, which is the opposite of how '$25' reads.[1]
−Doses are lower than the Wegovy tablet's, so it is the diabetes product rather than the weight one — and using it for weight is off-label.[1]
−Absorption depends on taking it fasting with a small sip of water and waiting 30 minutes, which is a stricter routine than a weekly injection.[1]

How this score is built

0.0/3.5Evidence — no weight-management trial figure recorded
3.0/3Approval — FDA approved for type 2 diabetes. Weight loss is off-label use.
0.0/2.5Cost — no verified price
0.0/1Caveats — −1.1: off-label for weight −0.4, strict dosing rules −0.2, boxed warning −0.5

The full formula →

Clinical evidence

FDA approved for type 2 diabetes. Weight loss is off-label use.

PIONEER trials in type 2 diabetes. Weight change was a secondary endpoint; the obesity trials of oral semaglutide were run at the higher doses sold as the Wegovy tablet rather than at these.

How long Rybelsus takes to work, and what each week costs →

What happens if you stop semaglutide: no Rybelsus trial stopped it on purpose, but Wegovy's label did, at a maintenance dose of 2.4 mg once weekly, or 1.7 mg (Rybelsus's is 7 mg or 14 mg once daily). The group that came off gained 6.9% of body weight in 48 weeks →

What you can take instead of Rybelsus, with each one's verified price →

What Rybelsus costs with insurance

There is no single figure, and any page giving one is describing a plan that is not necessarily yours. What decides it is below, and every part of it is checkable.

Rybelsus Savings Offer: As little as $25 for a 1-, 2- or 3-month prescription Who it is for: Commercially insured patients with coverage for Rybelsus (Novo's wording: "Eligible, commercially insured patients with product coverage only"). The catch: Capped at $100 of savings for a 1-month supply, $200 for two and $300 for three — two-thirds of the $150 Lilly allows on its Mounjaro and Trulicity cards, and the same as its Zepbound card, for the same $25 headline. At 7 mg and 14 mg the prescription itself has to be written as a 1-, 2- or 3-month supply to qualify; at 3 mg the offer is $25 a month. No annual ceiling and no fill limit is published on this page, and no end date either, which means the terms can change without one expiring.
It is closed to you if a government program pays for your care. Manufacturer copay cards exclude Medicare, Medicaid, TRICARE and VA beneficiaries by their own terms — a federal anti-kickback rule rather than a plan decision, so there is nothing to appeal. Which coupons you can actually use.
The indication on the prescription. A plan that excludes weight-loss drugs excludes the use, not the molecule — and Rybelsus is separately approved for glycemic control in type 2 diabetes, which that exclusion does not reach. What each drug is approved to treat.
If the answer is no. The cash price is what remains, and it is on this page. Every verified route to the same drug is priced with the date each was read.